Univariable Regression Models
| Variable . | P Value . | Overall Survival . | 95% CI . |
|---|---|---|---|
| Relative Risk . | |||
| Disease status3-150 | |||
| AML—CR1 | — | 1.0 | — |
| AML—CR2, RELU | .580 | 1.38 | 0.44-4.28 |
| AML—REL | .014 | 3.61 | 1.30-10.02 |
| MDS | — | — | — |
| EMD3-151 | |||
| No | — | 1.0 | — |
| Yes | .055 | 2.26 | 0.98-5.20 |
| Variable | P Value | DFS | 95% CI |
| Relative Risk | |||
| Disease status3-152 | |||
| AML—CR1 | — | 1.0 | — |
| AML—CR2, RELU | .445 | 1.49 | 0.54-4.13 |
| AML—REL | .037 | 2.67 | 1.06-6.70 |
| MDS | .121 | 0.19 | 0.02-1.54 |
| EMD3-153 | |||
| No | — | 1.0 | — |
| Yes | .030 | 2.36 | 1.09-5.14 |
| Variable | P Value | Relapse | 95% CI |
| Relative Risk | |||
| Disease status3-155 | |||
| AML—CR1 | — | 1.0 | — |
| AML—CR2, RELU | .359 | 1.70 | 0.55-5.32 |
| AML—REL | .019 | 3.45 | 1.23-9.66 |
| MDS | .194 | 0.25 | 0.03-2.04 |
| EMD3-154 | |||
| No | — | 1.0 | — |
| Yes | .080 | 2.12 | 0.92-4.93 |
| Variable . | P Value . | Overall Survival . | 95% CI . |
|---|---|---|---|
| Relative Risk . | |||
| Disease status3-150 | |||
| AML—CR1 | — | 1.0 | — |
| AML—CR2, RELU | .580 | 1.38 | 0.44-4.28 |
| AML—REL | .014 | 3.61 | 1.30-10.02 |
| MDS | — | — | — |
| EMD3-151 | |||
| No | — | 1.0 | — |
| Yes | .055 | 2.26 | 0.98-5.20 |
| Variable | P Value | DFS | 95% CI |
| Relative Risk | |||
| Disease status3-152 | |||
| AML—CR1 | — | 1.0 | — |
| AML—CR2, RELU | .445 | 1.49 | 0.54-4.13 |
| AML—REL | .037 | 2.67 | 1.06-6.70 |
| MDS | .121 | 0.19 | 0.02-1.54 |
| EMD3-153 | |||
| No | — | 1.0 | — |
| Yes | .030 | 2.36 | 1.09-5.14 |
| Variable | P Value | Relapse | 95% CI |
| Relative Risk | |||
| Disease status3-155 | |||
| AML—CR1 | — | 1.0 | — |
| AML—CR2, RELU | .359 | 1.70 | 0.55-5.32 |
| AML—REL | .019 | 3.45 | 1.23-9.66 |
| MDS | .194 | 0.25 | 0.03-2.04 |
| EMD3-154 | |||
| No | — | 1.0 | — |
| Yes | .080 | 2.12 | 0.92-4.93 |
Abbreviations: CR1, first complete remission; CR2, second complete remission; REL, relapse; RELU, untreated first relapse; 95% CI, 95% confidence interval.
Likelihood ratio test for entering presence of EMD into this model yields P = .24.
Among AML patients only; likelihood ratio test for entering stage of disease into this model yields P = .11.
Likelihood ratio test for entering presence of EMD into this model yields P = .14.
Among AML patients only; likelihood ratio test for entering stage of disease into this model yields P = .34.
Likelihood ratio test for entering presence of EMD into this model yields P = .43.
Among AML patients only; likelihood ratio test for entering stage of disease into this model yields P = .05.